Bavarian Nordic (OTCMKTS:BVNRY) Announces Quarterly Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) posted its quarterly earnings results on Friday. The company reported $0.72 EPS for the quarter, Zacks reports. The business had revenue of $281.11 million during the quarter. Bavarian Nordic had a return on equity of 12.35% and a net margin of 21.95%.

Bavarian Nordic Stock Down 5.9%

Shares of OTCMKTS BVNRY traded down $0.57 during midday trading on Friday, hitting $9.09. 4,654 shares of the company’s stock were exchanged, compared to its average volume of 6,711. The firm has a market capitalization of $2.16 billion, a PE ratio of 10.45 and a beta of 1.23. Bavarian Nordic has a 12 month low of $6.60 and a 12 month high of $13.00. The company’s 50 day moving average price is $11.79 and its 200 day moving average price is $10.61.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.